


# DS-1062 | TROP2 Targeted ADC

## CT Scan Findings in Dose Escalation

Decrease in the number of target and nontarget lesions in a patient treated with DS-1062 2.0 mg/kg

Target lesions



Baseline: Begin 2.0-mg/kg DS-1062a




Post-Cycle 4: After 3 months of treatment  
Maximum percent decrease in tumor size: 65.5%



Post-Cycle 10: After 7 months of treatment  
Maximum percent decrease in tumor size: 62.0%


Nontarget lesions



Baseline  
Begin DS-1062a 2.0-mg/kg therapy



Post-Cycle 4  
After 3 months of treatment




Post-Cycle 10  
After 7 months of treatment

Reproduced with permission of Toshio Shimizu, MD.  
ASCO 2019 Abstract #9051


# DS-1062 | TROP2 Targeted ADC

## CT Scan Findings in Dose Escalation

Reduction in the size of target lesion in a patient treated with  
DS-1062 4.0 mg/kg



**Baseline:** Begin 4.0-mg/kg DS-1062a



**Post-Cycle 6:** After 4.5 months of treatment  
*Maximum percent decrease in tumor size 36.6%*


Reproduced with permission of Jacob Sands, MD.

ASCO 2019 Abstract #9051

# DS-1062 | TROP2 Targeted ADC

## CT Scan Findings in Dose Escalation

Female, age 72 years with metastatic lung adenocarcinoma, s/p platinum/pemetrexed chemotherapy and immunotherapy, on 3rd-line DS-1062 (4 mg/kg dosing cohort)



Courtesy of Dr. Rebecca Heist and Dr. Jessica Lin, MGH, Boston, USA


ASCO 2019 Abstract #9051

## DS-1062 | TROP2 Targeted ADC CT Scan Findings in Dose Escalation

Reduction in the size of target lesion in a patient treated with  
DS-1062 8.0 mg/kg



**Baseline:** Begin 8.0-mg/kg DS-1062a




**Post-Cycle 2:** After 6 weeks of treatment  
*Maximum percent decrease in tumor size: 56%*

Reproduced with permission of Alexander Spira, MD.

ASCO 2019 Abstract #9051

# DS-1062 | TROP2 Targeted ADC

## Dose / Effect Spider Plot (preliminary data April 12, 2019)



\*3 additional PRs were confirmed after data cut-off